Generic Injectables Market Report by Therapeutic Area (Oncology, Anaesthesia, Anti-infectives, Parenteral Nutrition, Cardiovascular), Container (Vials, Ampoules, Premix, Prefilled Syringes), Distribution Channel (Hospitals, Retail Pharmacy), and Region 2024-2032

Generic Injectables Market Report by Therapeutic Area (Oncology, Anaesthesia, Anti-infectives, Parenteral Nutrition, Cardiovascular), Container (Vials, Ampoules, Premix, Prefilled Syringes), Distribution Channel (Hospitals, Retail Pharmacy), and Region 2024-2032

Report Format: PDF+Excel | Report ID: SR112024A804
Buy Now

Market Overview:

The global generic injectables market size reached US$ 47.5 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 90.9 Billion by 2032, exhibiting a growth rate (CAGR) of 7.2% during 2024-2032. The escalating prevalence of chronic diseases, rising healthcare expenditure, increasing patent expiration of branded drugs, recent technological advancements in drug formulation and delivery systems, and implementation of various regulatory support are some of the major factors propelling the market.

Report Attribute
Key Statistics
Base Year
2023
Forecast Years
2024-2032
Historical Years
2018-2023
Market Size in 2023 US$ 47.5 Billion
Market Forecast in 2032 US$ 90.9 Billion
Market Growth Rate 2024-2032 7.2%


Generic injectables refer to pharmaceutical drugs that are injected into the body and are equivalent to their brand-name counterparts in dosage, strength, quality, and performance. It includes various types, such as vaccines, insulin, and antibiotics. Generic injectables are widely used for a range of medical conditions, such as diabetes, cancer, hypertension, and infections. They also find extensive applications in anesthesia, hormone replacement, immunization, and emergency treatments. Generic injectables are safe and cost-effective medications that reduce the need for surgical interventions, provide targeted therapy, and have fewer side effects.

Generic Injectables Market

The recent technological advancements in drug formulation and delivery systems that are making production more efficient, thereby lowering costs and boosting availability, are propelling the market growth. Additionally, the implementation of various regulatory support and initiatives to create a conducive environment for manufacturers of generic injectables by streamlining approval processes is contributing to the market growth. Apart from this, the growing geriatric population, which requires more healthcare interventions, including injectables for various age-related ailments, is positively influencing the market growth. Furthermore, the rising preference for injectables over oral medications among patients due to quicker onset of action and higher bioavailability is strengthening the market growth. In addition, the rapid improvement in the supply chain, which has made the distribution of generic injectables more streamlined, is supporting the market growth.

Generic Injectables Market Trends/Drivers:

The escalating prevalence of chronic diseases

The escalating prevalence of chronic diseases is a primary driver of the generic injectables market. Conditions such as cancer, diabetes, and cardiovascular diseases (CVDs) are on a constant rise and require long-term treatments and medications. Generic injectables such as insulin for diabetes, chemotherapeutic agents for cancer, and antihypertensive medications for cardiovascular issues are indispensable in the management of these conditions. Furthermore, the affordability of generic injectables makes them accessible to a larger population, especially in low and middle-income countries where healthcare infrastructure may be limited or costly. Additionally, healthcare systems are focusing on balancing quality and cost-effectiveness. In line with this, generic injectables present a viable option, as they provide the necessary treatments at a fraction of the cost of their branded counterparts, thus facilitating more widespread disease management and containment.

The rising healthcare expenditure across the globe

The growing cost of healthcare is a significant concern for both developed and developing nations. There is an urgent need for affordable alternatives as treatment expenses are skyrocketing. In line with this, generic injectables offer a cost-effective solution without compromising on efficacy or safety. Furthermore, they can substantially lower the economic burden on patients and families. Additionally, they provide budget-constrained healthcare systems with the leeway to allocate resources more efficiently towards the improvement of healthcare services, research, or public health initiatives. Moreover, patients also benefit directly through lower out-of-pocket costs, making treatments more accessible. As a result, the rising cost of healthcare is compelling healthcare providers and patients to turn to generic injectables as a financially sustainable alternative.

The increasing patent expiration of branded drugs

Patent expirations of branded injectables present a golden opportunity for the generic injectables market. Expiry of the patent allows generic drug manufacturers to produce and sell copies of the branded medication. Furthermore, they can produce equivalent medications without incurring the initial research and development (R&D) costs, thereby passing on the savings to the consumers in the form of lower prices. Moreover, the generic versions usually receive faster regulatory approvals as they are bioequivalent to already-approved branded drugs. This not only speeds up the time-to-market but also broadens consumer access to essential medications. Additionally, patent expiry enables the mass production of medications that were previously restricted by intellectual property (IP) laws. As a result, patent expiration creates a conducive environment for the expansion of the generic injectables market, benefiting both manufacturers and consumers.

Generic Injectables Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global generic injectables market report, along with forecasts at the global, and regional levels for 2024-2032. Our report has categorized the market based on therapeutic area, container, and distribution channel.

Breakup by Therapeutic Area:

Generic Injectables Market

  • Oncology
  • Anaesthesia
  • Anti-infectives
  • Parenteral Nutrition
  • Cardiovascular
     

Oncology dominates the market

The report has provided a detailed breakup and analysis of the market based on therapeutic area. This includes oncology, anaesthesia, anti-infectives, parenteral nutrition, and cardiovascular. According to the report, oncology represented the largest segment.

Oncology is dominating the market due to the high prevalence of cancer, which necessitates a consistent and accessible supply of medications for treatment. Furthermore, cancer treatments are highly expensive, often requiring combinations of drugs and long-term administration. In line with this, generic injectables offer a cost-effective alternative to branded drugs, alleviating some of the financial burdens on healthcare systems and patients. Besides this, the oncology sector has witnessed patent expirations for branded drugs, thus opening up opportunities for generic pharmaceutical companies to introduce their versions of these medications. Moreover, the complexity of cancer treatment protocols, which often call for targeted therapies, is facilitating the demand for generic injectables. In addition, oncology treatments frequently necessitate hospitalization or clinical administration of drugs, where injectables are more commonly used.

Breakup by Container:

  • Vials
  • Ampoules
  • Premix
  • Prefilled Syringes
     

Vials exhibit a clear dominance in the market

A detailed breakup and analysis of the market based on the container has also been provided in the report. This includes vials, ampoules, premix, and prefilled syringes. According to the report, vials represented the largest segment.

Vials offer a high degree of sterility and contamination protection, which is essential for injectable drugs. The integrity of the medication is better preserved in a vial, which is a critical factor when dealing with sensitive substances, such as biologics or chemotherapy agents. Furthermore, they are incredibly versatile and can accommodate a wide range of drug volumes, from small quantities for specialized treatments to larger volumes for widespread applications. Additionally, vials are highly cost-effective, especially when produced in bulk. This cost advantage aligns well with the overall appeal of generic injectables as cost-effective alternatives to branded drugs.

Ampoules offer high barrier properties, ensuring that the medication inside remains sterile and free from contamination. Additionally, the glass construction of ampoules allows for high visibility, enabling healthcare professionals to visually inspect the solution for any impurities before administration, thus adding an extra layer of safety. Besides this, they are usually single-dose containers, which eliminates the risks associated with multi-dose vials, such as cross-contamination and dosing errors.

Breakup by Distribution Channel:

  • Hospitals
  • Retail Pharmacy
     

Hospitals holds the largest share in the market

A detailed breakup and analysis of the market based on distribution channel has also been provided in the report. This includes hospitals and retail pharmacy. According to the report, hospitals accounted for the largest market share.

Hospitals are dominating the market as they allow the immediate and precise administration of injectables, which is especially critical in emergency situations or intensive care units (ICUs) where quick onset of action can be lifesaving. Furthermore, they handle a high volume of patients and a broad array of medical conditions, ranging from surgeries to chronic disease management. The versatility of generic injectables allows them to be used across various departments, making them a go-to option for multiple therapeutic applications. Besides this, hospitals have the necessary infrastructure, including temperature-controlled storage and trained medical staff, to manage the complexities of injectable drug administration. Moreover, the growing pressure to manage healthcare costs effectively makes generic injectables a preferred choice for hospitals.

Breakup by Region:

Generic Injectables Market

  • Europe
  • North America
  • Asia 
  • Latin America
  • Middle East and Africa
     

North America exhibits a clear dominance, accounting for the largest generic injectables market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include Europe, North America, Asia, Latin America, and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America has a well-established healthcare system that readily adopts medical innovations, including generic injectables. Furthermore, the region has some of the highest per capita healthcare spending, allowing for the widespread use of both branded and generic pharmaceuticals. Additionally, the imposition of supportive policies by regional governments to streamline processes for the approval of generic medications, including injectables, is positively influencing the market growth. Besides this, the frequent expiry of branded medication patents in North America is creating opportunities for generic drug manufacturers to introduce their own, more affordable versions. Moreover, the escalating geriatric population, which requires more medical treatments, often leading to higher consumption of medications, including injectables, is acting as another growth-inducing factor. Along with this, the heightened awareness and acceptance among both healthcare providers and consumers regarding the efficacy and cost-effectiveness of generic medications is supporting the market growth.

Competitive Landscape:

Leading companies are consistently working to expand their range of generic injectable medications, including biosimilars, to cover a broader spectrum of therapeutic areas. Furthermore, they are investing in research and innovation to improve the formulation and stability of generic injectables, thereby enhancing their quality and market appeal. In addition, several key players are forming strategic partnerships with other industry stakeholders to enhance their capabilities, distribution networks, and product offerings. Besides this, companies are focusing on expanding their geographical reach through collaboration with local distributors or setting up manufacturing facilities. Additionally, they are working on optimizing their production processes to offer cost-effective solutions without compromising on quality. Moreover, major players are ensuring products meet the rigorous regulatory requirements, especially in highly regulated markets.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

  • Baxter International Inc.
  • Fresenius Kabi AG
  • Hikma Pharmaceuticals plc
  • Pfizer Inc.
  • Sagent Pharmaceuticals Inc. (Nichi-Iko Pharmaceutical Co. Ltd.)
  • Sandoz International GmbH (Novartis International AG)
  • Sanofi S.A.

Recent Developments:

  • In August 2023, Fresenius Kabi introduced Plerixafor Injection, which is a generic equivalent to Mozobil.
  • In June 2022, Hikma announced its entry into France with the establishment of Hikma France S.A.S, which will supply generic injectable medicines to hospitals in France.
  • In March 2021, Sandoz announced the availability of generic Treprostinil injection for the treatment of PAH patients in the US.

Generic Injectables Market Report Scope:

Report Features Details
Base Year of the Analysis 2023
Historical Period 2018-2023
Forecast Period 2024-2032
Units US$ Billion
Scope of the Report Exploration of Historical Trends and Market Outlook, Industry Catalysts and Challenges, Segment-Wise Historical and Predictive Market Assessment:
  • Therapeutic Area
  • Container
  • Distribution Channel
  • Region
Therapeutic Areas Covered Oncology, Anaesthesia, Anti-infectives, Parenteral Nutrition, Cardiovascular
Containers Covered Vials, Ampoules, Premix, Prefilled Syringes
Distribution Channels Covered Hospitals, Retail Pharmacy
Regions Covered Europe, North America, Asia, Latin America, Middle East and Africa
Companies Covered Baxter International Inc., Fresenius Kabi AG, Hikma Pharmaceuticals plc, Pfizer Inc., Sagent Pharmaceuticals Inc. (Nichi-Iko Pharmaceutical Co. Ltd.), Sandoz International GmbH (Novartis International AG), Sanofi S.A., etc.
Customization Scope 10% Free Customization
Report Price and Purchase Option Single User License: US$ 3899
Five User License: US$ 4899
Corporate License: US$ 5899
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

Key Benefits for Stakeholders:

  • IMARC’s industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the generic injectables market from 2018-2032.
  • The research report provides the latest information on the market drivers, challenges, and opportunities in the global generic injectables market.
  • The study maps the leading, as well as the fastest-growing, regional markets.
  • Porter's five forces analysis assist stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the generic injectables industry and its attractiveness.
  • Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.

Key Questions Answered in This Report

The global generic injectables market was valued at US$ 47.5 Billion in 2023.

We expect the global generic injectables market to exhibit a CAGR of 7.2% during 2024-2032.

The sudden outbreak of the COVID-19 pandemic has led to the easy availability of generic injectables via online pharmacies with free doorstep delivery, to combat the risk of the coronavirus infection.

The rising utilization of generic injectables in treating various cardiovascular disorders without affecting the efficacy of the treatment is primarily driving the global generic injectables market.

Based on the therapeutic area, the global generic injectables market can be segmented into oncology, anesthesia, anti-infectives, parenteral nutrition, and cardiovascular. Among these, oncology segment holds the majority of the total market share.

Based on the distribution channel, the global generic injectables market has been segregated into hospitals and retail pharmacy. Currently, hospitals hold the largest market share.

On a regional level, the market can be classified into Europe, North America, Asia, Latin America, and Middle East and Africa, where North America currently dominates the global market.

Some of the major players in the global generic injectables market include Baxter International Inc., Fresenius Kabi AG, Hikma Pharmaceuticals plc, Pfizer Inc., Sagent Pharmaceuticals Inc. (Nichi-Iko Pharmaceutical Co. Ltd.), Sandoz International GmbH (Novartis International AG) and Sanofi S.A.

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Generic Injectables Market Report by Therapeutic Area (Oncology, Anaesthesia, Anti-infectives, Parenteral Nutrition, Cardiovascular), Container (Vials, Ampoules, Premix, Prefilled Syringes), Distribution Channel (Hospitals, Retail Pharmacy), and Region 2024-2032
Purchase options




Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Get in Touch With Us
UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials

Aktive Services

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

Read More
Greenfish S.A.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

Read More
Colruyt Group

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Read More
KRISHAK BHARTI CO-OP LTD

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

Read More
Zee Media Corp. Ltd.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Read More
Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

Read More
Sumitomo Corporation

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

Read More
Hameln Rds

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

Read More
Quality Consultants BV

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

Read More
TATA Advanced Systems Limited

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

Read More
Stax

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

Read More